Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors

NCT07029399 is registered in ClinicalTrials.gov with NiKang Therapeutics, Inc. as lead sponsor.

NCT NCT07029399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07029399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors
Lead sponsor
NiKang Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 25, 2025
Completion date
December 31, 2027
Enrollment
361 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ccne1 amplified advanced solid tumors, hr+ breast cancer, hr+ her2- breast cancer, triple negative breast cancer (tnbc)